Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | Unmet needs in bladder cancer in the immunotherapy era

Andrea Apolo • 9 Feb 2018
GU Cancers 2018
Bladder Cancer Genitourinary Cancer

Despite there now being a variety of promising immunotherapies for bladder cancer, a large proportion of patients don’t respond to these. Speaking from the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA, Andrea Apolo, MD, of the National Cancer Institute, Bethesda, MD, discusses this issue.

More from Andrea Apolo

0:57
Biomarkers for muscle-invasive bladder cancer in the AMBASSADOR trial
Andrea Apolo • 25 Jan 2024
0:54
Assessing the role of perioperative immunotherapy in MIBC
Andrea Apolo • 25 Jan 2024
2:59
AMBASSADOR: adjuvant pembrolizumab in muscle-invasive urothelial carcinoma
Andrea Apolo • 25 Jan 2024
2:38
CheckMate 9ER: cabo-nivo superior to sunitinib in extended follow-up results
Andrea Apolo • 16 Feb 2021

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals